Kevin Bielamowicz
Sourced from institutional research profiles (UAMS TRI or ARA).
Researcher
Faculty Researcher
Research Areas
Biomedical Subjects
Biography and Research Information
OverviewAI-generated summary
Kevin Bielamowicz's research focuses on pediatric oncology and neuro-oncology, with a particular emphasis on developing and evaluating novel therapeutic strategies for brain tumors and other complex pediatric cancers. He has investigated CAR-T cell therapies targeting specific tumor antigens, such as HER2 and IL13Rα2, to mitigate tumor escape mechanisms. His work also includes evaluating the efficacy of targeted therapies, such as mirdametinib, in conditions like neurofibromatosis type 1-associated plexiform neurofibroma.
Bielamowicz has also contributed to understanding the outcomes of different radiotherapy techniques in pediatric medulloblastoma, comparing the incidence of endocrine deficiencies following proton and photon radiotherapy. His research extends to exploring combined immunotherapies for high-grade gliomas in the context of replication-repair deficiency syndromes and investigating the safety and efficacy of investigational agents in relapsed pediatric solid tumors, including medulloblastoma, neuroblastoma, and Ewing sarcoma.
His scholarly contributions are reflected in a h-index of 20 and over 3,200 citations across 166 publications. He is a designated high-impact researcher and leads a research group at the University of Arkansas for Medical Sciences. Key collaborators include Murat Gökden, Sateesh Jayappa, Kathleen Danielle Aldrich, and Gregory W. Albert, all from the University of Arkansas for Medical Sciences.
Metrics
- h-index: 20
- Publications: 166
- Citations: 3,320
Selected Publications
-
Targeted Inhibition in Pediatric MET and ALK-Altered Hemispheric Gliomas: Objective Responses Followed by Treatment Resistance (2025)
-
TARGETED INHIBITION IN PEDIATRIC MET and ALK ALTERED PEDIATRIC HIGH GRADE GLIOMAS: OBJECTIVE RESPONSES FOLLOWED BY TREATMENT RESISTANCE (2025)
-
Prognostic Features of Recurrent Midline and H3 K27M-Mutant Glioma (2025)
-
A rare presentation of pediatric germinoma mimicking optic pathway glioma: illustrative case (2025)
-
ReNeu: A Pivotal Phase 2b Trial of Mirdametinib in Children and Adults With Neurofibromatosis Type 1 (NF1)-Associated Symptomatic Plexiform Neurofibroma (PN) (S29.003) (2025)
-
QOL-08. HEALTH-RELATED QUALITY-OF-LIFE (HRQOL) IN ADULTS AND CHILDREN WITH NEUROFIBROMATOSIS TYPE 1-ASSOCIATED PLEXIFORM NEUROFIBROMA (NF1-PN) TREATED WITH MIRDAMETINIB: PIVOTAL, PHASE 2B RENEU TRIAL (2024)
-
ReNeu: A Pivotal, Phase IIb Trial of Mirdametinib in Adults and Children With Symptomatic Neurofibromatosis Type 1-Associated Plexiform Neurofibroma (2024)
Grants & Funding
As listed on this researcher's institutional profile.
- Multispecific CAR T Cells for the Tx of High Grade Glioma UAMS ACHRI Flow Through
Collaboration Network
Top Collaborators
- Comparison of hypothyroidism, growth hormone deficiency, and adrenal insufficiency following proton and photon radiotherapy in children with medulloblastoma
- Reevaluating surgery and re-irradiation for locally recurrent pediatric ependymoma—a multi-institutional study
- Re-Evaluating Surgery and Re-Irradiation for Locally Recurrent Pediatric Ependymoma — a Multi-Institutional Study
- Comparison of Endocrine Outcomes Following Proton and Photon Radiotherapy in Children With Medulloblastoma 
- ReNeu: A Pivotal, Phase IIb Trial of Mirdametinib in Adults and Children With Symptomatic Neurofibromatosis Type 1-Associated Plexiform Neurofibroma
- Reevaluating surgery and re-irradiation for locally recurrent pediatric ependymoma—a multi-institutional study
- ReNeu: A pivotal phase 2b trial of mirdametinib in children and adults with neurofibromatosis type 1 (NF1)-associated symptomatic inoperable plexiform neurofibroma (PN).
- Re-Evaluating Surgery and Re-Irradiation for Locally Recurrent Pediatric Ependymoma — a Multi-Institutional Study
- Comparison of hypothyroidism, growth hormone deficiency, and adrenal insufficiency following proton and photon radiotherapy in children with medulloblastoma
- Reevaluating surgery and re-irradiation for locally recurrent pediatric ependymoma—a multi-institutional study
- Comparison of Endocrine Outcomes Following Proton and Photon Radiotherapy in Children With Medulloblastoma 
- Central nervous system embryonal tumors with EWSR1-PLAGL1 rearrangements reclassified as INI-1 deficient tumors at relapse
- Targeted Inhibition in Pediatric MET and ALK-Altered Hemispheric Gliomas: Objective Responses Followed by Treatment Resistance
- ETMR-15. Central Nervous System Embryonal Tumor with EWSR1 translocation: Evolving changes in histology, sequencing, and epigenetics at relapse in 2 patients and potential treatment implications
- Central nervous system embryonal tumors with EWSR1-PLAGL1 rearrangements reclassified as INI-1 deficient tumors at relapse
- Targeted Inhibition in Pediatric MET and ALK-Altered Hemispheric Gliomas: Objective Responses Followed by Treatment Resistance
- ETMR-15. Central Nervous System Embryonal Tumor with EWSR1 translocation: Evolving changes in histology, sequencing, and epigenetics at relapse in 2 patients and potential treatment implications
- ReNeu: A Pivotal, Phase IIb Trial of Mirdametinib in Adults and Children With Symptomatic Neurofibromatosis Type 1-Associated Plexiform Neurofibroma
- ReNeu: A pivotal phase 2b trial of mirdametinib in children and adults with neurofibromatosis type 1 (NF1)-associated symptomatic inoperable plexiform neurofibroma (PN).
- Prognostic Features of Recurrent Midline and H3 K27M-Mutant Glioma
- Comparison of hypothyroidism, growth hormone deficiency, and adrenal insufficiency following proton and photon radiotherapy in children with medulloblastoma
- Comparison of Endocrine Outcomes Following Proton and Photon Radiotherapy in Children With Medulloblastoma 
- Comparison of hypothyroidism, growth hormone deficiency, and adrenal insufficiency following proton and photon radiotherapy in children with medulloblastoma
- Comparison of Endocrine Outcomes Following Proton and Photon Radiotherapy in Children With Medulloblastoma 
- Comparison of hypothyroidism, growth hormone deficiency, and adrenal insufficiency following proton and photon radiotherapy in children with medulloblastoma
- Comparison of Endocrine Outcomes Following Proton and Photon Radiotherapy in Children With Medulloblastoma 
- Comparison of hypothyroidism, growth hormone deficiency, and adrenal insufficiency following proton and photon radiotherapy in children with medulloblastoma
- Comparison of Endocrine Outcomes Following Proton and Photon Radiotherapy in Children With Medulloblastoma 
- Comparison of hypothyroidism, growth hormone deficiency, and adrenal insufficiency following proton and photon radiotherapy in children with medulloblastoma
- Comparison of Endocrine Outcomes Following Proton and Photon Radiotherapy in Children With Medulloblastoma 
- Comparison of hypothyroidism, growth hormone deficiency, and adrenal insufficiency following proton and photon radiotherapy in children with medulloblastoma
- Comparison of Endocrine Outcomes Following Proton and Photon Radiotherapy in Children With Medulloblastoma 
- Reevaluating surgery and re-irradiation for locally recurrent pediatric ependymoma—a multi-institutional study
- Re-Evaluating Surgery and Re-Irradiation for Locally Recurrent Pediatric Ependymoma — a Multi-Institutional Study
- Reevaluating surgery and re-irradiation for locally recurrent pediatric ependymoma—a multi-institutional study
- Re-Evaluating Surgery and Re-Irradiation for Locally Recurrent Pediatric Ependymoma — a Multi-Institutional Study
- Reevaluating surgery and re-irradiation for locally recurrent pediatric ependymoma—a multi-institutional study
- Re-Evaluating Surgery and Re-Irradiation for Locally Recurrent Pediatric Ependymoma — a Multi-Institutional Study
Similar Researchers
Based on overlapping research topics